# Baxano

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/baxano

- Industry: Medical Devices & Equipment
- Headquarters: San Jose, US
- Website: www.baxano.com
- Total disclosed funding: $50M
- Latest round: Series C (Jun 15, 2010)
- Investors on record: 7

## About

Baxano Inc. is a medical technology company focused on developing innovative solutions in spinal surgery, enhancing procedural efficiency and patient outcomes.Baxano Inc. specializes in the development of advanced surgical instruments for spinal procedures. Founded in 2005 and headquartered in San Jose, US, the company has undergone strategic pivots to refine its product offerings. The company raised USD 10 mn in Venture Debt in March 2014, bringing its total funds raised to USD 30 mn. Founder information is not disclosed.Baxano Inc. specializes in providing innovative spinal surgery solutions tailored to meet the specific needs of healthcare providers. Its product lineup includes advanced surgical instruments designed to enhance efficiency and address challenges in the spinal surgery sector. These tools are known for their functionality, allowing surgeons to perform procedures with improved precision and reduced recovery times. The company's clients include hospitals and surgical centers, utilizing these solutions for a range of surgical interventions. Geographically, Baxano has established a presence in North America, delivering its products to a broad audience within the medical field.The company's revenue model revolves primarily around B2B sales, including multi-year contracts with healthcare institutions. Clients engage with Baxano through structured agreements centered on its flagship surgical products. Pricing plans are designed to accommodate various customer segments, ensuring accessibility for both small and large healthcare providers. This approach fosters long-term relationships, contributing to a stable revenue stream.Baxano Inc. plans to leverage its recent funding of USD 10 mn from March 2014 to accelerate the development of new surgical instruments targeted for launch in 2025. The company aims to expand its market presence into Europe and Asia Pacific by 2026, capitalizing on growing demand for spinal surgery solutions in these regions. The funding will also support research and development initiatives to enhance product offerings and address emerging market needs.

## Funding rounds

- Series C, Jun 15, 2010, $30M — Athenian Venture Partners, Prospect Venture Partners, Three Arch Partners, Affinity Capital Management, Presidio Partners, Kearny Venture Partners, Kaiser Permanente Ventures
- Series B, Sep 2, 2008, $20M — Prospect Venture Partners, Three Arch Partners, Kearny Venture Partners

## Investors

- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B, Series C
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series B, Series C
- Kearny Venture Partners (https://capitalatlas.ai/funds/kearny-venture-partners) — Series B, Series C
- Athenian Venture Partners (https://capitalatlas.ai/funds/athenian-venture-partners) — Series C
- Affinity Capital Management (https://capitalatlas.ai/funds/affinity-capital-management) — Series C
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C